Intra-Cellular Therapies Inc. (ITCI)
ITCI moved a median of -0.04% 30 minutes after news, and -0.11% by the close. How ITCI actually reacts to news — the realized, point-in-time move the market made, measured across 247 labeled events over the last three years with zero look-ahead.
ITCI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 226 |
| 30-min | -0.04% | 44% | 226 |
| 60-min | -0.00% | 50% | 226 |
| to close | -0.11% | 41% | 226 |
| Middle 50% of ITCI reactions | -0.57% to +0.36% |
|---|---|
| Median reaction (30-min) | -0.04% |
| Measured reactions | 247 |
Half of all Intra-Cellular Therapies Inc. news events land between -0.57% and +0.36% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ITCI reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 20 | -0.04% | 25% | -0.15% |
| Coverage initiations | 15 | -0.03% | 13% | -0.09% |
| Rating reiterations | 65 | +0.00% | 51% | -0.08% |
| Price-target raises | 21 | -0.44% | 24% | -0.72% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how ITCI ranks against every other measured name →
That’s how ITCI usually reacts — get an email when it moves on news →Email me when ITCI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ITCI's baseline. Nothing else.
Recent ITCI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Intra-Cellular Therapies | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT Intra-Cellular Therapies | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K Intra-Cellular Therapies For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM Intra-Cellular Therapies | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form POSASR Intra-Cellular Therapies | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS Intra-Cellular Therapies | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K Intra-Cellular Therapies For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | -0.03% | |
| Form 10-K/A Intra-Cellular Therapies For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.04% | +0.08% | |
| Form 8-K Intra-Cellular Therapies For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | +0.06% | +0.06% | |
| Form 8-K Intra-Cellular Therapies For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -0.00% | -0.05% | |
| ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders | Press release | Business Wire | -0.04% | -0.02% | |
| Form 10-K Intra-Cellular Therapies For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.02% | -0.01% | |
| Form 8-K Intra-Cellular Therapies For: Feb 21 | SEC filing · Form 8-K | SEC EDGAR | -0.02% | -0.01% | |
| Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results | Press release | GlobeNewswire | -0.02% | -0.01% | |
| Form DEFM14A Intra-Cellular Therapies | SEC filing · Form DEFM14A | SEC EDGAR | +0.20% | +0.45% | |
| Form PREM14A Intra-Cellular Therapies For: Feb 05 | SEC filing · Form PREM14A | SEC EDGAR | +0.14% | +0.03% | |
| Form 8-K Intra-Cellular Therapies For: Jan 10 | SEC filing · Form 8-K | SEC EDGAR | -0.19% | -0.61% | |
| Form DEFA14A Intra-Cellular Therapies | SEC filing · Form DEFA14A | SEC EDGAR | -0.19% | -0.61% | |
| ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-Cellular Therapies, Inc. Is Fair to Shareholders | Press release | Business Wire | -0.19% | -0.61% | |
| Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. | Press release | GlobeNewswire | -0.19% | -0.61% | |
| Form 8-K Intra-Cellular Therapies For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +8.75% | +9.64% | |
| Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz | Press release | GlobeNewswire | +8.75% | +9.64% | |
| Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.05% | -2.31% | |
| Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting | Press release | GlobeNewswire | -1.68% | +0.55% | |
| Form 8-K Intra-Cellular Therapies For: Dec 03 | SEC filing · Form 8-K | SEC EDGAR | -0.58% | -0.81% | |
| Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy | Press release | GlobeNewswire | -0.58% | -0.81% | |
| Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences | Press release | GlobeNewswire | -0.02% | +0.86% | |
| Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress | Press release | GlobeNewswire | +0.16% | +0.72% | |
| Form 8-K Intra-Cellular Therapies For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | +0.46% | +4.02% | |
| Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia | Press release | GlobeNewswire | +0.46% | +4.02% | |
| Form 10-Q Intra-Cellular Therapies For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +7.11% | +8.34% | |
| Form 8-K Intra-Cellular Therapies For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | +7.11% | +8.34% | |
| Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance | Press release | GlobeNewswire | +7.11% | +8.34% | |
| Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast | Press release | GlobeNewswire | +0.16% | +2.90% | |
| Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress | Press release | GlobeNewswire | -0.33% | -2.58% | |
| Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences | Press release | GlobeNewswire | -0.41% | -1.26% | |
| Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference | Press release | GlobeNewswire | -0.27% | +1.00% | |
| Form 10-Q Intra-Cellular Therapies For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.76% | -4.31% | |
| Form 8-K Intra-Cellular Therapies For: Aug 02 | SEC filing · Form 8-K | SEC EDGAR | -1.76% | -4.31% | |
| Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer | Press release | GlobeNewswire | -1.76% | -4.31% | |
| Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance | Press release | GlobeNewswire | -1.76% | -4.31% | |
| Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast | Press release | GlobeNewswire | -0.81% | -0.78% | |
| Form S-8 Intra-Cellular Therapies | SEC filing · Form S-8 | SEC EDGAR | +0.06% | -0.80% | |
| Form 8-K Intra-Cellular Therapies For: Jun 14 | SEC filing · Form 8-K | SEC EDGAR | -0.67% | +0.42% | |
| Form 8-K Intra-Cellular Therapies For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -2.29% | -0.78% | |
| Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder | Press release | GlobeNewswire | -2.29% | -0.78% | |
| Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference | Press release | GlobeNewswire | -0.82% | +1.33% | |
| Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.06% | +2.27% | |
| Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting | Press release | GlobeNewswire | -2.16% | -5.19% | |
| Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences | Press release | GlobeNewswire | -1.00% | -5.79% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ITCI section they belong to.
Where else ITCI is measured.
ITCI earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MELINTA THERAPEUTICS INC (MLNT) | 248 | -0.38% | 34% |
| Heron Therapeutics, Inc. (HRTX) | 247 | -0.34% | 42% |
| Avadel Pharmaceuticals plc - Ordinary Share (AVDL) | 246 | -0.16% | 42% |
| Cumberland Pharmaceuticals Inc. (CPIX) | 245 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Intra-Cellular Therapies Inc.'s median reaction calculated?
Every labeled ITCI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 247 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of ITCI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ITCI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.